Nov. 19, 2019 Price forecast | 2 weeks: 0.20% | 1 month: 1.09% | 3 months: 1.83%


NEO stock forecast

Our latest prediction for NeoGenomics, Inc.'s stock price was made on the Nov. 19, 2019 when the stock price was at 24.22$.

In the short term (2weeks), NEO's stock price should outperform the market by 0.20%. During that period the price should oscillate between -5.94% and +5.83%.

In the medium term (3months), NEO's stock price should outperform the market by 1.83%. During that period the price should oscillate between -14.40% and +17.93%.

Create a solid portfolio with NEO

Add NEO to your portfolio and optimize it!


About NeoGenomics, Inc.

NeoGenomics, Inc. is a clinical laboratory company, which specializes in cancer genetics diagnostic testing and pharma services. It operates through the Clinical Services and Pharma Services segments. The Clinical Services segment offers cancer testing services to community-based pathologists, hospitals, academic centers, and oncology groups. The Pharma Services segment focuses on supporting pharmaceutical firms in drug development programs by supporting various clinical trials. The company was founded by Michael T. Dent on October 29, 1998 and is headquartered in Fort Myers, FL.

At the moment the company generates 378M USD in revenues.

On its last earning announcement, the company reported a profit of 0.02$ per share.

The book value per share is 2.00$

NeoGenomics, Inc. website


Three months stock forecastNov. 19, 2019


Financials

Revenue USD Gross Margin Operating Income Operating Margin Net Income Earnings Per Share Dividends Payout Ratio Shares Book Value Per Share Operating Cash Flow Cap Spending Free Cash Flow
378M 48.60% 14M 3.60% 2M 0.02 - - 101M 2.00 35M -17M 18M